Cambridge Investment Research Advisors Inc. Purchases Shares of 21,119 Tempus AI, Inc. (NASDAQ:TEM)

Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 21,119 shares of the company's stock, valued at approximately $1,019,000.

Several other hedge funds and other institutional investors have also made changes to their positions in TEM. Cherry Tree Wealth Management LLC bought a new stake in Tempus AI during the 1st quarter valued at $31,000. Operose Advisors LLC bought a new stake in Tempus AI during the 4th quarter valued at $25,000. Farther Finance Advisors LLC acquired a new position in shares of Tempus AI during the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC increased its stake in shares of Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after acquiring an additional 965 shares during the period. Finally, NewEdge Advisors LLC acquired a new position in shares of Tempus AI during the fourth quarter valued at approximately $49,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Trading Up 2.5%

NASDAQ TEM opened at $60.65 on Friday. Tempus AI, Inc. has a twelve month low of $30.81 and a twelve month high of $91.45. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.56 and a current ratio of 1.71. The stock has a market cap of $10.50 billion and a price-to-earnings ratio of -7.78. The firm's 50 day moving average price is $62.53 and its two-hundred day moving average price is $54.12.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.03. Tempus AI had a negative net margin of 88.27% and a negative return on equity of 533.21%. The firm had revenue of $255.74 million for the quarter, compared to analysts' expectations of $248.13 million. Tempus AI's revenue was up 75.4% on a year-over-year basis. Equities analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current year.

Insider Activity

In other news, COO Ryan Fukushima sold 20,000 shares of the business's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $52.36, for a total transaction of $1,047,200.00. Following the transaction, the chief operating officer directly owned 884,460 shares in the company, valued at $46,310,325.60. The trade was a 2.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the business's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $70.07, for a total transaction of $17,517,500.00. Following the transaction, the chief executive officer owned 9,357,283 shares in the company, valued at approximately $655,664,819.81. This represents a 2.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 607,522 shares of company stock worth $41,300,238. 27.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Piper Sandler raised their price objective on shares of Tempus AI from $55.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, May 15th. Morgan Stanley lifted their price target on shares of Tempus AI from $60.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. BTIG Research initiated coverage on shares of Tempus AI in a research report on Monday, April 21st. They issued a "buy" rating and a $60.00 price target on the stock. Guggenheim lifted their price target on shares of Tempus AI from $65.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, June 30th. Finally, Needham & Company LLC restated a "buy" rating and issued a $70.00 price target on shares of Tempus AI in a research report on Wednesday, May 7th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $63.67.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.